var data={"title":"Botulism immune globulin (intravenous human): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Botulism immune globulin (intravenous human): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5753?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=botulism-immune-globulin-intravenous-human-drug-information\" class=\"drug drug_general\">see &quot;Botulism immune globulin (intravenous human): Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142084\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>BabyBIG</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045616\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immune Globulin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442089\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Infant botulism:</b> Dosage is specific to the manufactured lot. As of November 2013: IV: Total dose is 50 mg/kg as a single IV infusion. Start as soon as diagnosis of infant botulism is made; refer to product specific information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045609\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=botulism-immune-globulin-intravenous-human-drug-information\" class=\"drug drug_general\">see &quot;Botulism immune globulin (intravenous human): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: <b>Infant botulism:</b> Infants: Dosage is specific to the manufactured lot. As of November 2013: IV: Total dose is 50 mg/kg as a single IV infusion. Start as soon as diagnosis of infant botulism is made; refer to product specific information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Infants: Infusion reactions: Slow the infusion rate or temporarily interrupt infusion for minor reaction (ie, flushing). Discontinue infusion and administer epinephrine for anaphylactic reaction or significant hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants: There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; the rate of infusion and concentration of solution should be minimized in patients with renal impairment or those at risk for renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142070\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BabyBIG: ~ 100 mg [contains albumin (human), sucrose; supplied with diluent]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142058\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217339\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Access to botulism immune globulin is restricted through the Infant Botulism Treatment and Prevention Program (IBTPP). Healthcare providers must contact the IBTPP on-call physician at (510) 231-7600 to review treatment indications and to obtain the medication.  For more information, refer to http://www.infantbotulism.org or contact IBTPP@infantbotulism.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045620\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">IV infusion: Infusion should be started within 2 hours of reconstitution and be completed within 4 hours of reconstitution. <b>Do not administer IM or SubQ. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Initial: Begin at 25 mg/kg/hour for the first 15 minutes; if well tolerated may increase to a maximum rate of 50 mg/kg/hour; infusion should take 67.5 minutes to complete at the recommended rates and should be concluded within 4 hours of reconstitution (unless infusion rate is decreased or temporarily interrupted due to an adverse reaction). Use low volume tubing for administration via a separate line. If this is not possible, piggyback BabyBIG into a preexisting line containing either NS or a dextrose solution (D<sub>2.5</sub>W, D<sub>5</sub>W, D<sub>10</sub>W, or D<sub>20</sub>W) with or without added NaCl. Do not dilute more than 1:2 with any of the above solutions. Drug concentration should be no less than 25 mg/mL. Administer via an in-line or syringe-tip filter (18  micron). Do not administer if solution is turbid. Infusion should be slowed or temporarily interrupted for minor side effects; discontinue in case of hypotension or anaphylaxis. Epinephrine should be available for the treatment of acute allergic reaction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142080\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution, store between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Infusion should begin within 2 hours of reconstitution and be completed within 4 hours of reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045619\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of infant botulism caused by toxin type A or B (FDA approved in ages &lt;1 year) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6049723\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">BabyBIG may be confused with HBIG</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142098\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported in open-label study except where otherwise noted; may reflect pathophysiology of infant botulism. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cold exremities, decreased blood pressure (transient), edema, heart murmur, increased blood pressure (transient), tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, decreased body temperature, irritability, neurologic abnormality (neurogenic bladder)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Contact dermatitis, erythematous rash, pallor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Dehydration, hyponatremia, metabolic acidosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distention, dysphagia, loose stools, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, decreased hemoglobin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Erythema at injection site, injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otitis media (reported in placebo-controlled study)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Abnormal breath sounds (decreased), atelectasis, cough, dyspnea, lower respiratory tract infection, nasal congestion, oxygen saturation decreased, rales, rhonchi, stridor, tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever, infusion related reaction (related to rate: &lt;5%, includes back pain, chills, fever, muscle cramps, nausea, vomiting, wheezing)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142075\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to human immune globulin preparations or any component of the formulation; selective immunoglobulin A deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142061\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1 mg/mL) should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (&ge;2 g/kg).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolysis: Immune globulin intravenous (IGIV) has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperproteinemia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur following administration of IGIV products; distinguish hyponatremia from pseudohyponatremia to prevent volume depletion, a further increase in serum viscosity and a higher risk of thrombotic events. These adverse events have not reported with botulism immune globulin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with IGIV use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function. Usually occurs within 1-6 hours after infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure) can rarely occur; usually within 7 days of use (more likely with products stabilized with sucrose). Use with caution in patients with renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Thrombotic events have been reported with administration of IGIV; use with caution in patients with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity. Infuse at lowest practical rate in patients at risk for thrombotic events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypovolemia: Patients should not be volume depleted prior to therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adults: Not indicated for use in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Safety and efficacy established for infants &lt;1 year of age; not indicated for children &ge; 1 year of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: For IV infusion only; do not exceed recommended rate of administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298879\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142065\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13285&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142076\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Botulism immune globulin is only indicated for use in infants &lt;1 year of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045615\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs and blood pressure monitored continuously during the infusion. BUN and serum creatinine should be monitored prior to initial infusion. Periodic monitoring of renal function tests and urine output in patients at risk for developing renal failure. Aseptic  meningitis syndrome (may occur hours to days following IGIV therapy). Signs of relapse (may occur up to 1 month following recovery).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142060\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">BIG-IV is purified immunoglobulin derived from the plasma of adults immunized with botulinum toxoid types A and B. BIG-IV provides antibodies to neutralize circulating toxins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142074\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Half-life elimination: Infants: 28 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11277184\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prior to November 2013, dosing recommendations were for <b>Lot 4</b> for a total dose of 75 mg/kg/dose.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Arnon SS, Schechter R, Maslanka SE, et al, &quot;Human Botulism Immune Globulin for the Treatment of Infant Botulism,&quot; <i>N Engl J Med</i>, 2006, 354(5):462-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/botulism-immune-globulin-intravenous-human-pediatric-drug-information/abstract-text/16452558/pubmed\" target=\"_blank\" id=\"16452558\">16452558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BabyBIG (BIG-IV) (botulism immune globulin) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; October 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infant Botulism Treatment and Prevention Program, Department of Communicable Disease Control, California Department of Health Services, http://infantbotulism.org</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Underwood K, Rubin S, Deakers T, et al, &quot;Infant Botulism: A 30-Year Experience Spanning the Introduction of Botulism Immune Globulin Intravenous in the Intensive Care Unit at Childrens Hospital Los Angeles,&quot; <i>Pediatrics</i>, 2007, 120(6):e1380-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/botulism-immune-globulin-intravenous-human-pediatric-drug-information/abstract-text/18055655/pubmed\" target=\"_blank\" id=\"18055655\">18055655</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13285 Version 70.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F142084\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045616\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442089\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045609\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F142070\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F142058\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11217339\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045620\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F142080\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045619\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6049723\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F142098\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F142075\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F142061\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298879\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F142065\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F142076\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045615\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F142060\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F142074\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F11277184\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13285|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=botulism-immune-globulin-intravenous-human-drug-information\" class=\"drug drug_general\">Botulism immune globulin (intravenous human): Drug information</a></li></ul></div></div>","javascript":null}